FY2025 · period end Dec '25 · from the 10-K filed Feb 13, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B |
| Gross Profit | $10.35B | $9.49B | $8.61B | $7.85B | $6.67B |
| Operating Income | $4.17B | negative: -$0.23B | $3.83B | $4.31B | $2.78B |
| Net Income | $3.95B | negative: -$0.54B | $3.62B | $3.32B | $2.34B |
| EPS (Diluted) | $15.32 | negative: -$2.08 | $13.89 | $12.82 | $9.01 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $25.64B | $22.53B | $22.73B | $18.15B | $13.43B |
| Total Liabilities | $6.98B | $6.12B | $5.15B | $4.24B | $3.33B |
| Stockholders' Equity | $18.67B | $16.41B | $17.58B | $13.91B | $10.10B |
| Cash & Equivalents | $5.08B | $4.57B | $10.37B | $10.50B | $6.79B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $3.63B | negative: -$0.49B | $3.54B | $4.13B | $2.64B |
| Capital Expenditures | $0.44B | $0.30B | $0.20B | $0.20B | $0.23B |
| Free Cash Flow | $3.19B | negative: -$0.79B | $3.34B | $3.93B | $2.41B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 86.2% | 86.1% | 87.2% | 87.9% | 88.1% |
| Operating Margin | 0.3% | negative: -0.0% | 0.4% | 0.5% | 0.4% |
| Net Margin | 0.3% | negative: -0.0% | 0.4% | 0.4% | 0.3% |
| Return on Equity | 22.5% | negative: -3.2% | 23.0% | 27.7% | 24.9% |
| Return on Assets | 16.4% | negative: -2.4% | 17.7% | 21.0% | 18.6% |
| Debt / Equity | — | — | — | — | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001193125-26-296710 | Jul 6, 2026 | Jul 7, 2026 | Jul 7, 2026 01:55 UTC | EDGAR |
| 8-K | 0000875320-26-000204 | May 13, 2026 | May 13, 2026 | May 13, 2026 20:03 UTC | EDGAR |
| 10-Q | 0000875320-26-000173 | Mar 31, 2026 | May 5, 2026 | May 5, 2026 20:08 UTC | EDGAR |
| 8-K | 0000875320-26-000171 | May 4, 2026 | May 4, 2026 | May 4, 2026 20:05 UTC | EDGAR |
| 8-K | 0000875320-26-000166 | Apr 28, 2026 | Apr 29, 2026 | Apr 29, 2026 20:05 UTC | EDGAR |
| 8-K | 0000875320-26-000147 | Mar 31, 2026 | Mar 31, 2026 | Mar 31, 2026 20:03 UTC | EDGAR |
| 10-K | 0000875320-26-000056 | Dec 31, 2025 | Feb 13, 2026 | Feb 13, 2026 21:20 UTC | EDGAR |
| 8-K | 0000875320-26-000034 | Feb 12, 2026 | Feb 12, 2026 | Feb 12, 2026 21:04 UTC | EDGAR |
Direct links to SEC EDGAR. VRTX has additional filings available on the SEC site.
6 numbers VERTEX PHARMACEUTICALS INC / MA later changed — same XBRL tag, both filings linked.
Income (Loss) from Continuing Operations before Income Taxes, Domestic·FY 2013
Major restatementwas-$390M
Revised up in a 10-K.
Operating Income (Loss)·3 months to Dec 2013
Major restatementwas-$274.2M
Revised up in a 10-K.
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest·3 months to Dec 2013
Major restatementwas-$340.3M
Revised up in a 10-K.
Income (Loss) from Continuing Operations before Income Taxes, Foreign·FY 2012
Major restatementwas-$269.2M
Revised up in a 10-K.
Net Cash Provided by (Used in) Operating Activities·FY 2013
Major restatementwas-$51.6M
Revised down in a 10-K.
Operating Income (Loss)·Q2 2013
Major restatementwas-$56.9M
Revised up in a 10-K.
VRTX is not the only one.
See every restatement we've found across the market — or get an alert the next time VRTX revises a number.
Restatements are detected by comparing every vintage of a fact across all of VERTEX PHARMACEUTICALS INC / MA's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows VRTX's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling VERTEX PHARMACEUTICALS INC / MA — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on VRTX yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on VRTX and publish the result to your public profile.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs